Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study

被引：0
|
作者：
Bartlett, Nancy L.
Dickinson, Michael
Hutchings, Martin
Carlo-Stella, Carmelo
Wu, Shang-Ju
Leppa, Sirpa
Trneny, Marek
Corradini, Paolo
Offner, Fritz
Mulvihill, Estefania
Bottos, Alessia
Chohan, Saibah
Baumlin, Pauline
Relf, James
Lundberg, Linda
Bachy, Emmanuel
机构：
[1] Washington Univ, St Louis, MO USA
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Rigshosp, Copenhagen, Denmark
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Humanitas Univ, Milan, Italy
[6] IRCCS Humanitas Res Hosp, Milan, Italy
[7] Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Univ Helsinki, Helsinki, Finland
[9] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[10] Charles Univ Prague, Prague, Czech Republic
[11] Univ Milan, Milan, Italy
[12] Ist Nazl Tumori, Fdn Ist Ricovero & Cura & Carattere Sci IRCCS, Milan, Italy
[13] Univ Ziekenhuis, Ghent, Belgium
[14] F Hoffmann La Roche Ltd, Basel, Switzerland
[15] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[16] La Roche Prod Ltd, Welwyn Garden City, Herts, England
[17] Hosp Civils Lyon, Pierre Benite, France
[18] Univ Claude Bernard, Pierre Benite, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7020
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non- Hodgkin Lymphoma (NHL) Patients (pts)
    Dickincon, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Patel, Krish
    Khan, Cyrus
    Barlett, Nancy L.
    Iacoboni, Gloria
    Hertzberg, Mark
    Leppa, Sirpa
    Van Den Neste, Eric
    Tani, Monica
    Cartron, Guillaume
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    BLOOD, 2021, 138
  • [22] Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
    Wiernik, P. H.
    Lossos, I. S.
    Tuscano, J.
    Justice, G.
    Vose, J. M.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Habermann, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] GLOFITAMAB STEP-UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS)
    Carlo-Stella, C.
    Hutchings, M.
    Offner, F. C.
    Morschhauser, F.
    Bachy, E.
    Crump, M.
    Sureda, A.
    Iacoboni, G.
    Haioun, C.
    Perez-Callejo, D.
    Lundberg, L.
    Relf, J.
    Clark, E.
    Carlile, D.
    Piccione, E.
    Belousov, A.
    Humphrey, K.
    Dickinson, M. J.
    Corradini, P.
    HAEMATOLOGICA, 2021, 106 (10) : 9 - 9
  • [24] Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma
    Witzig, Thomas E.
    Vose, Julie M.
    Moore, Timothy D.
    Reeder, Craig B.
    Cole, Craig E.
    Justice, Glen
    Kaplan, Henry P.
    Voralia, Michael
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Wiernik, Peter H.
    BLOOD, 2007, 110 (11) : 754A - 755A
  • [25] Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
    Witzig, T. E.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Glofitamab step-up dosing: updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts)
    Carlo-Stella, C.
    Hutchings, M.
    Offner, F. C.
    Morschhauser, F.
    Bachy, E.
    Crump, M.
    Sureda, A.
    Iacoboni, G.
    Haioun, C.
    Perez-Callejo, D.
    Lundberg, L.
    Relf, J.
    Clark, E.
    Carlile, D.
    Piccione, E.
    Belousov, A.
    Humphrey, K.
    Dickinson, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 131 - 131
  • [27] Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
    Witzig, Thomas E.
    Vose, Julie M.
    Zinzani, Pier Luigi
    Reeder, Craig B.
    Buckstein, Rena
    Polikoff, Jonathan
    Guo, Pingshan
    Pietronigro, Dennis
    Ervin-Haynes, Annette
    Czuczman, Myron S.
    BLOOD, 2009, 114 (22) : 668 - 669
  • [28] Clofarabine (CLO) is active in patients (pts) with refractory and/or relapsed non-Hodgkin's lymphoma (NHL): A phase I/II study
    Nabhan, Chadi
    Fried, Walter
    Galvez, Angel G.
    Venugopal, Parameswaran
    Gozun, Phillip
    Bitran, Jacob D.
    BLOOD, 2007, 110 (11) : 186B - 186B
  • [29] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [30] Phase II study of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymhoma (NHL)
    Younes, A
    McLaughlin, P
    Pro, B
    Hagemeister, F
    Bleyer, A
    BLOOD, 2003, 102 (11) : 639A - 640A
12345